ConductScience.org, home

Paper41202502

Retreatment, rechallenge, and escalation with subsequent immune checkpoint inhibitor therapies across cancers after initial failure.

da Silva IP and 11 others. ESMO Open, 2025. Cited by 10 papers, by iCite.

Cite this record

ConductScience Library. Retreatment, rechallenge, and escalation with subsequent immune checkpoint inhibitor therapies across cancers after initial failure. Papers, record 41202502. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41202502

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Retreatment, rechallenge, and escalation with subsequent immune checkpoint inhibitor therapies across cancers after initial failure.
PubMed
Journal
ESMO Open
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
10
iCite
Relative citation ratio, by iCite
2.02, provisional
iCite
Revised in PubMed
2026-09-25
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1da Silva IPI P
2Zimmer LL
3Blay JYJ-Y
4Maio MM
5Larkin JJ
6Grimm MOM-O
7Puri SS
8Butler MOM O
9Patel SS
10Thakkar PKP K
11Long GVG V
12Melero II

Source PubMed

Download CSV of authors

Topics5

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Immune Checkpoint InhibitorsMajor topic
NeoplasmsMajor topic
Humans
Retreatment
Treatment Failure

References79

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
137348035Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma.J Clin Oncol2023https://conductscience.org/library/papers/37348035PubMed
235832458Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with stage IV non-small cell lung cancer: a retrospective study.Transl Lung Cancer Res2022https://conductscience.org/library/papers/35832458PubMed
338722641Nivolumab + Ipilimumab as Immunotherapeutic Boost in Metastatic Urothelial Carcinoma: A Nonrandomized Clinical Trial.JAMA Oncol2024https://conductscience.org/library/papers/38722641PubMed
430231380Patterns of Response and Progression to Immunotherapy.Am Soc Clin Oncol Educ Book2018https://conductscience.org/library/papers/30231380PubMed
531050774Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs.JAMA Netw Open2019https://conductscience.org/library/papers/31050774PubMed
636780608Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial.J Clin Oncol2023https://conductscience.org/library/papers/36780608PubMed
732605892Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer Patients.Clin Lung Cancer2020https://conductscience.org/library/papers/32605892PubMed
834986285Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.N Engl J Med2022https://conductscience.org/library/papers/34986285PubMed
934254534Outcomes after retreatment with MAPK inhibitors and immune checkpoint inhibitors in melanoma patients.Future Oncol2021https://conductscience.org/library/papers/34254534PubMed
1037071838Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up.J Clin Oncol2023https://conductscience.org/library/papers/37071838PubMed
1132078391Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study.J Clin Oncol2020https://conductscience.org/library/papers/32078391PubMed
1233303685Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients.Science2021https://conductscience.org/library/papers/33303685PubMed
1333894335Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189.Ann Oncol2021https://conductscience.org/library/papers/33894335PubMed
1437852736Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0.J Immunother Cancer2023https://conductscience.org/library/papers/37852736PubMed
1535222642REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study.J Oncol2022https://conductscience.org/library/papers/35222642PubMed
1633945288Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.J Clin Oncol2021https://conductscience.org/library/papers/33945288PubMed
1735867951
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination.
J Clin Oncol2023https://conductscience.org/library/papers/35867951PubMed
1828650338IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.J Clin Invest2017https://conductscience.org/library/papers/28650338PubMed
1932681091Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer.Nat Commun2020https://conductscience.org/library/papers/32681091PubMed
2033857412Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.Lancet Oncol2021https://conductscience.org/library/papers/33857412PubMed

See all 79 referencesDownload CSV of references

Cited by8

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.

PMIDTitleJournalYearIn PapersSource
42707037Cancer survivorship in malignant melanoma.J Dtsch Dermatol Ges2026https://conductscience.org/library/papers/42707037PubMed
42449707Rational Immune Checkpoint Inhibitor-Based Combination Immunotherapy in Cancer: Mechanistic Design, Biomarker Selection, and Implications for Oncology Pharmacy.Cancers (Basel)2026https://conductscience.org/library/papers/42449707PubMed
42343297Therapeutic outcomes of PD-1 blockade-related regimens versus docetaxel in previously immunotherapy-treated advanced non-small cell lung cancer: a retrospective, exploratory study.BMC Cancer2026https://conductscience.org/library/papers/42343297PubMed
42014741Microbiota-derived metabolites as modulators of cancer immunotherapy response.Nat Commun2026https://conductscience.org/library/papers/42014741PubMed
41963855Efficacy and safety of albumin-bound paclitaxel combined with anlotinib and immunotherapy in advanced non-small cell lung cancer with liver metastases: a retrospective study.BMC Cancer2026https://conductscience.org/library/papers/41963855PubMed
41898300Targeting T-Cells for Cancer Treatment: Current Clinical Strategies and Challenges.Biomedicines2026https://conductscience.org/library/papers/41898300PubMed
41883115Systemic Therapy for Advanced Hepatocellular Carcinoma in 2026: Current Standard-of-Care and Emerging Therapeutic Strategies.J Gastroenterol Hepatol2026https://conductscience.org/library/papers/41883115PubMed
41816339Evolving epidemiology and improving safety of rechallenge in immune checkpoint inhibitor-associated acute kidney injury: an updated meta-analysis.Front Immunol2026https://conductscience.org/library/papers/41816339PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41202502

GET https://conductscience.org/api/papers/v1/41202502/references?page=2